Less_Lipoatrophy_and_Better_Lipid_Profile_With.3英文文献资料.pdfVIP

CLINICAL SCIENCE Less Lipoatrophy and Better Lipid Profile With Abacavir as Compared to Stavudine 96-Week Results of a Randomized Study Daniel Podzamczer, MD,* Elena Ferrer, MD,* Pochita Sanchez, RN,* Jose´ M. Gatell, MD,† Manel Crespo, MD,‡ Cesar Fisac, RD,§ Montse Lonca, MD,† Jose Sanz, MD, k Jordi Niubo, PharmD,¶ Sergio Veloso, MD,# Josep M. Llibre, MD,** Pilar Barrufet, MD,†† Marı´a A. Ribas, MD,‡‡ Esperanza Merino, MD,§§ Esteban Ribera, MD,‡ Javier Martı´nez- Lacasa, MD, kk Carlos Alonso, MD,¶¶ Miquel Aranda, MD,## Federico Pulido, MD,*** Juan Berenguer, MD,††† Antonio Delegido, MD,‡‡‡ Juan D. Pedreira, MD,§§§ Ana Le´rida, MD, kkk Rafael Rubio, MD,*** and Luis del Rı´o, MD¶¶¶ for the ABCDE (Abacavir vs. d4T (stavudine) plus efavirenz) Study Team presented more favorable changes in the levels of triglycerides (P = Objective: To assess lipoatrophy, other toxicities, and efficacy as- 0.03), high-density lipoprotein cholesterol (HDLc; P , 0.001), and sociated with abacavir as compared with stavudine in HIV-infected apolipoprotein A1 (P , 0.001) as well as in the ratio between antiretroviral-naive patients. total cholesterol and HDLc (P = 0.005). Throughout the study, a higher proportion of patients in the stavudine group received lipid- Methods: This was a prospective, randomized, open trial, stratified by